AGIOS PHARMACEUTICALS, INC. (AGIO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 12,455 | 8,726 | 8,964 | 8,615 |
| Selling, general and administrative | 45,869 | 41,527 | 38,537 | 35,536 |
| Research and development | 91,940 | 72,743 | 72,455 | 77,401 |
| Cost of sales | 1,702 | 1,085 | 783 | 1,495 |
| Total operating expenses | 139,511 | 115,355 | 111,775 | 114,432 |
| Loss from operations | -127,056 | -106,629 | -102,811 | -105,817 |
| Interest income, net | 14,513 | 16,087 | 13,059 | 8,120 |
| Other income, net | 523 | 1,253 | 1,651 | 1,579 |
| Milestone payment from gain on sale of oncology business | - | - | 200,000 | - |
| Gain on sale of contingent payments | - | - | 889,136 | - |
| Net income (loss) before taxes | - | - | 1,001,035 | - |
| Income tax expense | - | - | 53,120 | - |
| Net loss | -112,020 | -89,289 | 947,915 | -96,118 |
| Net income (loss) per share - basic (in usd per share) | -1.93 | -1.55 | 16.65 | -1.69 |
| Net income (loss) per share - diluted (in usd per share) | -1.93 | -1.55 | 16.22 | -1.69 |
| Weighted-average number of common shares used in computing net income (loss) per share diluted (in shares) | 57,932,576 | 57,459,195 | 58,432,796 | 56,802,546 |
| Weighted-average number of common shares used in computing net income (loss) per share - basic (in shares) | 57,932,576 | 57,459,195 | 56,939,403 | 56,802,546 |